NCT00407537
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
See it on ClinicalTrials.gov ↗1,461 people
48%
52%
702 womenmiddle line = equal numbers759 men
- Phase
- PHASE4
- Paid for by
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Finished
- 2009-10
- Health conditions
- Hypertension, Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 35 Years – 79 Years
- Average age
- Not reported
- Age 65+
- 36.8%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions.”
Study titles and rules are shown in their original English.